pki-587 and Carcinoma--Pancreatic-Ductal

pki-587 has been researched along with Carcinoma--Pancreatic-Ductal* in 2 studies

Other Studies

2 other study(ies) available for pki-587 and Carcinoma--Pancreatic-Ductal

ArticleYear
Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Cancer biology & therapy, 2019, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Diphenylamine; Drug Screening Assays, Antitumor; Humans; MAP Kinase Signaling System; Morpholines; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; TOR Serine-Threonine Kinases; Triazines

2019
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 11-01, Volume: 28, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Kinase Kinases; Morpholines; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Triazines

2017